Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) Shares Purchased by SG Americas Securities LLC

SG Americas Securities LLC increased its position in shares of Atea Pharmaceuticals, Inc. (NASDAQ:AVIR) by 23.3% in the 4th quarter, Holdings Channel.com reports. The firm owned 42,521 shares of the company’s stock after acquiring an additional 8,024 shares during the quarter. SG Americas Securities LLC’s holdings in Atea Pharmaceuticals were worth $130,000 at the end of the most recent quarter.

Several other hedge funds and other institutional investors have also recently bought and sold shares of AVIR. Royal Bank of Canada increased its position in Atea Pharmaceuticals by 123.6% during the third quarter. Royal Bank of Canada now owns 4,536 shares of the company’s stock worth $26,000 after purchasing an additional 2,507 shares during the last quarter. Gladius Capital Management LP boosted its stake in Atea Pharmaceuticals by 98.2% during the third quarter. Gladius Capital Management LP now owns 8,581 shares of the company’s stock worth $26,000 after buying an additional 4,251 shares during the period. Osaic Holdings Inc. boosted its stake in Atea Pharmaceuticals by 93.3% during the second quarter. Osaic Holdings Inc. now owns 7,154 shares of the company’s stock worth $27,000 after buying an additional 3,453 shares during the period. Advisor Group Holdings Inc. boosted its stake in Atea Pharmaceuticals by 78.8% during the first quarter. Advisor Group Holdings Inc. now owns 4,070 shares of the company’s stock worth $28,000 after buying an additional 1,794 shares during the period. Finally, Point72 Middle East FZE purchased a new position in Atea Pharmaceuticals during the second quarter worth about $32,000. 86.67% of the stock is currently owned by institutional investors and hedge funds.

Insider Activity

In other news, insider Andrea Corcoran sold 15,843 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $3.84, for a total value of $60,837.12. Following the completion of the transaction, the insider now owns 670,208 shares of the company’s stock, valued at $2,573,598.72. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. In other news, insider Andrea Corcoran sold 15,843 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $3.84, for a total value of $60,837.12. Following the completion of the transaction, the insider now owns 670,208 shares of the company’s stock, valued at $2,573,598.72. The transaction was disclosed in a legal filing with the SEC, which is available at the SEC website. Also, CEO Jean-Pierre Sommadossi sold 56,910 shares of the firm’s stock in a transaction that occurred on Thursday, February 1st. The shares were sold at an average price of $3.85, for a total transaction of $219,103.50. Following the completion of the transaction, the chief executive officer now directly owns 116,557 shares of the company’s stock, valued at approximately $448,744.45. The disclosure for this sale can be found here. Over the last quarter, insiders sold 85,230 shares of company stock valued at $327,852. 14.50% of the stock is currently owned by company insiders.

Atea Pharmaceuticals Price Performance

Shares of AVIR stock opened at $3.71 on Thursday. The firm has a market cap of $312.25 million, a PE ratio of -2.26 and a beta of 0.16. The company has a 50-day moving average of $4.02 and a two-hundred day moving average of $3.50. Atea Pharmaceuticals, Inc. has a 1-year low of $2.77 and a 1-year high of $5.19.

Atea Pharmaceuticals (NASDAQ:AVIR) last announced its earnings results on Wednesday, February 28th. The company reported ($0.47) earnings per share for the quarter, missing the consensus estimate of ($0.44) by ($0.03). Sell-side analysts anticipate that Atea Pharmaceuticals, Inc. will post -2.76 EPS for the current fiscal year.

Atea Pharmaceuticals Company Profile

Atea Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, discovers, develops, and commercializes antiviral therapeutics for patients with viral infections. Its lead product candidate is AT-527, an oral antiviral candidate that is in Phase 3 SUNRISE-3 clinical trial for the treatment of patients with COVID-19.